Apotheca Biosciences (PCFP) Begins Shipping ProMED CBD, Our Newest Flag-Ship Pharma Grade CBD Product Line by ProMED Biosciences - Company Begins with 11 Product SKUs increasing to 30 Product SKUs by Second Quarter
SAINT PETERSBURG, FL, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations, and cannabis delivery technologies for the health care and consumer care industry, is pleased to announce incorporation of its newly created subsidiary ProMED Biosciences, Inc. ProMED Biosciences will ship their newest flag-ship pharma grade CBD product line under the trademarked brand name ProMED. Company expects substantial revenue potential from ProMED subsidiary with close to $500K in preorders so far.
ProMED Biosciences will be the Company’s consumer product division carrying cannabinoids and particularly cannabidiol(CBD) related products from tinctures to water and cosmetics. ProMED will be distributed nationally in wellbeing centers, dispensaries, spas, health food stores, vitamin shops, health care providers, online and through distributors.
ProMED will initially carry 11 product SKUs which includes:
-- 500 mg 30 ml CBD Oil Drops (Isolate) -- 500 mg 30 ml CBD Oil Drops (Full Spectrum) -- 1000 mg 30 ml CBD Tincture (Isolate) -- 1000 mg 30 ml CBD Tincture (Full Spectrum) -- 250 mg 3.4oz Air Pump Pain Cream (Isolate) -- 250 mg 3.4oz Air Pump Pain Cream (Full Spectrum) -- 25 mg Soft Gel Capsule 30 count bottle (Isolate) -- 25 mg Soft Gel Capsule 30 count bottle (Full Spectrum) -- 25 mg Dry Cap Sleep Aid 30 count bottle (Isolate) -- 500 mg OTC Sport Pain Cream (Isolate) -- 320 mg OTC Sport Pain Balm Stick (Isolate)
Full Traceability and Transparency
Our products are carefully developed and formulated from proprietary strains of hemp that have been derived from fully traceable USDA registered industrial hemp farms with full ISO and GMP-compliant traceability reports and COAs. Products have been and may be formulated and manufactured in an FDA registered, ISO 9001-22716, cGMP and OTC certified facilities.
Second Quarter 2019 product SKUs will include:
-- Crystal Resistant Broad Spectrum Vape Juices in 1000 & 1500 mg -- Hemp Cigarettes -- Cosmetic Line (Limited line) -- Broad Spectrum THC Free Pain Creams in 1000 mg -- Full & Broad Spectrum Gel Caps & Sleep Capsules in 1000 & 1500 mg -- Broad Spectrum THC Free Tinctures & Oil Drops in 1000 & 1500 mg -- Water Soluble Powders & Liquids -- Pure CBD Crystalline Isolate Nano Water Soluble Liquid Concentrates
Future product SKUs in development in 2019 will include:
-- Bath Salts & Soaks -- Beverages (Water) -- Body Lotion, Oils & Sprays -- Body Wash -- Breath Fresheners -- Creams & Lotions -- Energy Shots -- Eye Drops & Lubricants -- Facial Creams -- Hand & Foot Care -- Hemp Cigarettes -- Infused Topical Patches -- Lip Balm -- Mouthwash -- Muscle Balm -- Oral Pain Relievers -- Personal Lubricants -- Pet CBD -- Salves & Topicals -- Shampoos & Conditioners -- Skin Care -- SPF Sunblock -- Toothpaste & Whitening -- Vape Juice & Cartridges
The success behind ProMED is the strategic partnerships that have been formed by Apotheca Biosciences, its parent company. Apotheca Biosciences has been on the cutting edge of formulations and strategic partnerships, dedicated to the very best products and formulations that give the consumer of our product piece of mind that they are getting the very best CBD products on today’s market.
We utilize a CO2 extraction that allows us to draw the CBD from the plant material and filter out unnatural substances, maximizing pure CBD concentration with 0% THC. In addition, we will go a step further and place QR codes on every single product to provide a (COA) Certificate of Analysis on the spot to any customer! In addition every single product will be laser etched with a batch number that will match the (COA). ProMED CBD will always provide a superior product by making sure we are the leader in transparency.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabiosciences.com.
About ProMED Biosciences Inc. – Science Based Wellbeing
ProMED Biosciences is a developer and manufacturer of medical grade CBD and cannabinoids products that enhances wellbeing and quality of life. ProMED is and will be distributed nationally in wellbeing centers, dispensaries, Spas, health food stores, Vitamin Shops, health care provider’s offices, online and through distributors.
To request further information about ProMED, please email firstname.lastname@example.org, or visit it on FB @promedcbd and Twitter @promedbio.
About Apotheca Biosciences Inc.
Apotheca Biosciences, a biopharmaceutical company, through its divisions, engages in 1) the discovery, development, and commercialization of therapies for the treatment of opioid addiction, sleep disorder, PTSD. Alzheimer’s and inflammatory diseases worldwide, 2) develops and manufactures medical devices for precise dosing, and 3) direct to business and consumer CBD enhanced supplements, formulations and cosmetics. The pipeline of products includes, transdermal, sublingual, digestive technologies and medical devices for precise and controlled dosing of cannabinoids. Products such as CannaDERME, a transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds for the general pain market.
To request further information about Apotheca, please email email@example.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca.
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
-- Apotheca Biosciences Inc.
Contact: Media Contact: (727) 228-3994 Apotheca Biosciences http://www.apothecabio.com firstname.lastname@example.org Twitter - @apotheca Facebook – apotheca Telegram- apotheca